For a smoker who has decided to quit, the range of available tools has never been wider — and the guidance on which to use has never been more contested. Traditional nicotine replacement therapy products, licensed by medicines regulators and with decades of clinical trial evidence, sit alongside e-cigarettes with their growing but still shorter-term evidence base, and the newer category of nicotine pouches that occupy a distinct pharmacological and situational niche. Making an informed choice between these options, or deciding how to combine them, requires understanding what each product is actually doing and what the evidence says about outcomes.
This guide provides a clear, evidence-grounded comparison of the three categories: traditional NRT products including patches, gum, lozenges, and inhalers; vaping devices and e-liquids; and tobacco-free nicotine pouches. The goal is not to advocate for one approach over another but to give smokers trying to quit the information they need to make a genuinely informed choice.
Traditional Nicotine Replacement Therapy: The Established Evidence Base
Nicotine replacement therapy products have been available in Ireland since the 1980s and have an extensive clinical trial evidence base. A 2018 Cochrane systematic review — the gold standard for evidence synthesis in health research — analysed over one hundred and thirty randomised controlled trials involving more than sixty-four thousand participants and found that NRT increased the rate of quitting smoking by fifty to sixty percent compared to placebo. This is a robust finding that has been replicated consistently across diverse populations and settings.
The key products in the NRT category and their characteristics: patches deliver a steady, sustained nicotine release over sixteen or twenty-four hours, maintaining blood nicotine at a relatively stable level that prevents acute withdrawal without producing sharp peaks. They require no active management during the day and are the simplest format to use correctly. Their limitation is the absence of the immediate craving relief that smokers associate with the act of lighting a cigarette — a situational craving that arrives quickly and requires a fast response.
Nicotine gum and lozenges provide faster-acting relief than patches and are used responsively — when cravings arise — rather than continuously. They are effective at acute craving management but require correct technique: gum must be chewed using the “chew and park” method to release nicotine into the buccal mucosa rather than into the stomach, and neither product should be consumed with acidic drinks in the preceding thirty minutes, as acid inhibits absorption. These technique requirements are not always communicated clearly to users, leading to suboptimal outcomes.
The nicotine inhaler is the NRT product that most closely replicates the behavioural dimension of smoking. It is a cartridge-based device that delivers nicotine through the oral and pharyngeal mucosa when puffed, rather than to the lungs. The act of using it provides the hand-to-mouth ritual that many smokers identify as one of the most difficult aspects of quitting. Clinical evidence for the inhaler is positive, though the product is less widely available and less frequently recommended than patches and gum.
Combining NRT products — typically a patch for baseline delivery plus a fast-acting product for acute cravings — is better supported by evidence than using a single product alone. Combination NRT has consistently higher quit rates than monotherapy in clinical trials.
Vaping as a Cessation Tool: What the Evidence Shows
The evidence base for vaping as a smoking cessation tool has grown substantially since the first randomised controlled trials in the early 2010s. The most influential study to date is the RESCUE trial published in the New England Journal of Medicine in 2019, which compared e-cigarettes to combination NRT in a UK NHS smoking cessation service. After one year, 18% of the e-cigarette group had quit smoking compared to 9.9% of the NRT group — a near doubling of quit rate that reached statistical significance and changed the policy landscape in the UK substantially.
Subsequent systematic reviews have broadly confirmed this finding, though effect sizes vary across studies and settings. The overall conclusion from NICE in England, and now reflected in HSE guidance in Ireland, is that e-cigarettes are at least as effective as NRT for smoking cessation and possibly more effective, particularly when accompanied by behavioural support.
The mechanism of vaping’s superiority over traditional NRT, where it exists, is likely multi-factorial. E-cigarettes more closely replicate the pharmacokinetic profile of cigarette nicotine delivery than any NRT product — nic salt e-liquids in particular produce a faster absorption curve that more effectively addresses acute craving. They also replicate the behavioural dimension of smoking — the hand-to-mouth action, the inhale-exhale ritual, the social element — in a way that patches and gum do not. And they are used in the same environmental contexts as cigarettes, providing a direct substitute in the situations that trigger cravings most powerfully.
The key limitation of vaping as a cessation tool is the potential for ongoing nicotine dependence. A vaper who successfully quits cigarettes but continues vaping indefinitely has reduced their harm exposure substantially but has not achieved nicotine freedom. For many people, this represents a satisfactory outcome — harm reduction rather than total cessation. For those whose goal is complete nicotine independence, vaping should ideally be a stepping stone with a planned reduction strategy, rather than a permanent replacement.
Nicotine Pouches: A New Tool With a Specific Niche
The evidence base for nicotine pouches as a cessation tool is less developed than for either traditional NRT or vaping, primarily because the category is newer and has not yet been the subject of large randomised controlled trials with cessation as the primary endpoint. What is available includes several observational studies, smaller clinical trials, and substantial pharmacokinetic data on nicotine absorption characteristics that allow comparison with established products.
Pharmacokinetically, nicotine pouches occupy a position between patches and fast-acting NRT. They absorb more quickly than patches but more slowly than nic salt vaping, producing a sustained release over the wearing period that effectively addresses the background nicotine need without producing the sharp peaks associated with cigarettes or nic salt e-liquids. This profile makes them less suited to acute craving relief in the immediate moment of a strong craving, but highly effective for maintaining comfortable nicotine levels across extended periods where vaping is not possible.
The specific niche where pouches outperform both traditional NRT and vaping is situational versatility. They can be used anywhere, in any situation, without any device, without producing any vapour or smell, and without any visible evidence of use. This absolute situational freedom is not replicated by any other nicotine delivery format. For smokers whose triggers are concentrated in specific situations — high-pressure meetings, long flights, formal social occasions — pouches may be the most effective tool for those specific moments even if another product handles their baseline nicotine management.
Comparing Quit Rates: What the Numbers Mean
Comparing quit rates across NRT, vaping, and pouches is complicated by differences in study design, population characteristics, and definitions of success. The most robust comparison is between NRT and vaping from the clinical trial literature: vaping appears to have higher quit rates, particularly in the context of NHS or HSE stop-smoking service support. NRT versus pouches cannot yet be rigorously compared for lack of equivalent trial data.
What the numbers consistently show is that all three categories perform better than unaided quitting, and that combination approaches — using multiple products to address different aspects of the smoking habit — outperform single-product strategies. A smoker who uses a patch for baseline nicotine maintenance, a refillable pod device for situational craving relief and behavioural substitution, and a tin of pouches for the specific situations where vaping is not available has covered their nicotine management needs more comprehensively than any single product can achieve.
The Irish HSE stop-smoking service offers individual consultations that can help smokers navigate these options in the context of their specific smoking pattern, trigger profile, and personal circumstances. These consultations are free, available across the country, and consistently underused relative to the number of Irish smokers who would benefit from them.
Making the Choice That Works for You
The best quit aid is the one you will actually use consistently. All three categories — traditional NRT, vaping, and pouches — have meaningful evidence behind them and can support successful cessation. The factors that predict success are not primarily about which specific product is chosen but about how consistently it is used, whether it adequately addresses your nicotine needs, and whether you have combined it with some form of behavioural support.
If you have tried NRT previously and found it insufficient — which is a common experience, particularly if you were using a single product and not combining it with behavioural support — this does not mean NRT cannot work for you. It may mean you needed a higher dose, a different product combination, or more behavioural support than you had. Similarly, a previous failed attempt with vaping may reflect a device or liquid choice that was not well-matched to your needs rather than an inherent limitation of the approach.
Talking to a pharmacist about your options takes fifteen minutes and is available without an appointment in every pharmacy in Ireland. Pharmacists are trained in smoking cessation and can advise on product selection, dosing, and combination strategies based on your specific smoking pattern. This consultation is one of the most underutilised resources in Irish smoking cessation, and for many smokers it is the most efficient use of time available in the process of choosing how to quit.